There is evidence to suggest that SGLT-2 inhibitors can prevent heart failure (HF) in patients with T2DM and decrease major adverse cardiovascular events and hospitalization for HF in patients with concomitant HF and T2DM [59,60]. Here, SLC5A2 is linked to heart failure.